71
Participants
Start Date
August 1, 2024
Primary Completion Date
July 18, 2025
Study Completion Date
July 18, 2025
HEMLIBRA
Emicizumab (Hemlibra, also known as ACE910 and RO5534262) is a humanized monoclonal modified immunoglobulin G4 (IgG4) antibody with a bispecific antibody structure produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells.
Comprehensive Center for Hemophilia and Coagulation Disorders (Cornell), New York
Children's Hospital at Montefiore, The Bronx
Northwell Health Hemostasis and Thrombosis Center, Staten Island
SUNY Upstate Hemophilia Treatment Center - HTC 058, Syracuse
Western NY Blood Care - Research Foundation for SUNY, Buffalo
Mary M Gooley Hemophilia Center, Inc., Rochester
Connecticut Children's Hemophilia Treatment Center - Connecticut Children's Medical Center, Hartford
Yale Hemophilia Treatment Center, New Haven
Dartmouth Hitchcock Hemophilia Center - Mary Hitchcock Memorial Hospital, Lebanon
Newark Beth Israel, Newark
Collaborators (1)
Genentech, Inc.
INDUSTRY
Regional Comprehensive Hemophilia Treatment Center (Mount Sinai)
UNKNOWN
Massachusetts General Comprehensive Hemophilia and Thrombosis Treatment Center
UNKNOWN
Rutgers Robert Wood Johnson Medical School
OTHER
Montefiore Medical Center
OTHER